Unique ID issued by UMIN | UMIN000048232 |
---|---|
Receipt number | R000054966 |
Scientific Title | The eff ect of ingestion of fermented soymilk foods containing lactic acid bacteria and bifi dobacteria in healthy adults double-blind randomized control crossover study. |
Date of disclosure of the study information | 2022/07/04 |
Last modified on | 2024/06/03 09:55:53 |
The eff ect of ingestion of fermented soymilk foods containing lactic acid bacteria and bifi dobacteria in healthy adults double-blind randomized control crossover study.
The eff ect of ingestion of fermented soymilk foods containing lactic acid bacteria and bifi dobacteria in healthy adults double-blind randomized control crossover study.
The eff ect of ingestion of fermented soymilk foods containing lactic acid bacteria and bifi dobacteria in healthy adults double-blind randomized control crossover study.
The eff ect of ingestion of fermented soymilk foods containing lactic acid bacteria and bifi dobacteria in healthy adults double-blind randomized control crossover study.
Japan |
NO
Adult |
Others
NO
This study aims to examine eff ects of a test food for the intestinalfunction and its Safety.
Safety,Efficacy
intestinal function:
questionnaire for stool scale(weekly)
stool frequency and number of defecation days(weekly)
safety:
Hematologic, Blood biochemical test(week0,week4)
Side eff ects/ Adverse events. (week0, week4)
Interventional
Cross-over
Randomized
Cluster
Double blind -all involved are blinded
Placebo
2
Treatment
Food |
Oral intake of the test product (1 pack a day,4weeks).
Oral intake of the placebo product (1 pack a day; 4weeks).
20 | years-old | <= |
65 | years-old | > |
Male and Female
(1) from 20years old to 65years old.
(2) Individuals whose written informed consent has been obtained after explanation of this study.
(1) patient
(2) individuals who are sensitive to test product or other foods, and medical products.
(3) individuals judged inappropriate for the study by the principal.
20
1st name | Iwahori |
Middle name | |
Last name | Yoshihiro |
Nihon-pharmaceutical Univercity
NO
362-0806
10281, Komuro, ina-cho, kita-adati-gun, saitama pref. Japan
08073457947
y-iwahori@nichiyaku.ac.jp
1st name | Iwahori |
Middle name | |
Last name | Yoshihiro |
Evidence Marketing LLC
NO
1770031
1-14-26, miharadai, nerima-ku, Tokyo, Japan
08073457947
info@evi-ma.com
Evidence Marketing LLC
KOEI SCIENCE LABORATORY Co., Ltd.
Profit organization
LLC Okutoeru
4-18-21, Minami-aoyama, Minato-ku, Tokyo, Japan
03-6864-7123
info@okutoeru.com
NO
2022 | Year | 07 | Month | 04 | Day |
https://www.jstage.jst.go.jp/article/jim/36/4/36_199/_pdf
Published
https://www.jstage.jst.go.jp/article/jim/36/4/36_199/_pdf
20
Subjects who took the test diet containing FF16 (150 mg/day) showed statistically significant improvements in the overall score of the Japanese Constipation Rating Scale, frequency of defecation, anal pain during defecation, and defecation status compared to before the intervention.
2024 | Year | 06 | Month | 03 | Day |
Subjects were 41-61 years old with 3-5 bowel movements per week.
as above
none
intestinal function
questionnaire for stool scale(weekly)
stool frequency and number of defecation days(weekly)
Completed
2022 | Year | 06 | Month | 01 | Day |
2022 | Year | 06 | Month | 15 | Day |
2022 | Year | 07 | Month | 04 | Day |
2022 | Year | 09 | Month | 30 | Day |
Different tests for two test foods (Solution A and Solution B) with the same scientific test name.
2022 | Year | 07 | Month | 02 | Day |
2024 | Year | 06 | Month | 03 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000054966